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Members of transforming growth factor-beta (TGF-b) superfamily play pivotal roles in development in multicellular
organisms. We report the functional characterization of the Schistosoma mansoni type II receptor (SmTbRII). Mining of
the S. mansoni expressed sequence tag (EST) database identified an EST clone that shows homology to the kinase
domain of type II receptors from different species. The amplified EST sequence was used as a probe to isolate a cDNA
clone spanning the entire coding region of a type II serine/threonine kinase receptor. The interaction of SmTbRII with
SmTbRI was elucidated and shown to be dependent on TGF-b ligand binding. Furthermore, in the presence of human
TGF-b1, SmTbRII was able to activate SmTbRI, which in turn activated SmSmad2 and promoted its interaction with
SmSmad4, proving the transfer of the signal from the receptor complex to the Smad proteins. Gynaecophoral canal
protein (GCP), whose expression in male worms is limited to the gynaecophoric canal, was identified as a potential TGF-
b target gene in schistosomes. Knocking down the expression of SmTbRII using short interfering RNA molecules (siRNA)
resulted in a concomitant reduction in the expression of GCP. These data provide evidence for the direct involvement
of SmTbRII in mediating TGF-b–induced activation of the TGF-b target gene, SmGCP, within schistosome parasites. The
results also provide additional evidence for a role for the TGF-b signaling pathway in male-induced female
reproductive development.
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Introduction
Members of the transforming growth factor-beta (TGF-b)
superfamily of secreted polypeptide growth factors play
important and diverse roles in cellular growth, differentia-
tion, extracellular matrix formation, and immunosuppression
[1–8]. The classical paradigm of TGF-b signaling has been
elucidated through numerous studies of different model
organisms (for detailed reviews see [9–18]). TGF-b mitogenic
effects are mediated through binding to the corresponding
plasma membrane receptors of the serine/threonine receptor
kinase family. This family of membrane receptors is divided
into two subclasses of distinct but structurally related
receptors. The type II receptor binds TGF-b and then
recruits the corresponding type I receptor to form an active
ligand–receptor complex, in which the type I receptor gets
phosphorylated and activated by the type II receptor.
Phosphorylation occurs on the serine and threonine residues
in a domain in the juxtamembrane region called the GS
domain [19,20]. The activated type I receptor relays the signal
to the next component of the signaling pathway, a member of
the Smad family of TGF-b signal transducers, the receptor-
regulated Smad or R-Smad. Upon phosphorylation by the
type I receptor, the R-Smad forms a hetero-oligomeric
complex with a common Smad or a Co-Smad (Smad4)
[21,22]. The newly formed Smad complex then translocates
into the nucleus where it binds nuclear proteins that direct
the Smad complexes to speciﬁc promoter sequence(s), where
they regulate the transcription of the target gene(s) to exert
the speciﬁc cellular responses triggered by ligand activation.
Structurally, members of the receptor family consist of
relatively short cysteine-rich, three-ﬁnger toxin fold extrac-
ellular domains [23], single transmembrane (TM) domains,
and intracellular regions composed mainly of the serine/
threonine kinase domains [24–26]. Not only the speciﬁcity of
TGF-b signaling is determined by the type I receptor
activation by type II receptor, but also the downstream
transmission of signals by the type I receptor is dependent on
its binding to and subsequent activation by type II receptor.
In general, type II receptors are constitutively active kinases
[19,27–29] that undergo reorientation of the intracellular
domains upon ligand binding, which results in activation of
the recruited type I receptor [30].
Flat worms of the genus Schistosoma cause schistosomiasis, a
Editor: Jim Tracy, University of Wisconsin-Madison, United States of America
Received January 12, 2006; Accepted April 26, 2006; Published June 16, 2006
DOI: 10.1371/journal.ppat.0020054
Copyright:  2006 Osman et al. This is an open-access article distributed under the
terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Abbreviations: aa, amino acids; BAC, bacterial artificial chromosome; bp, base
pairs; ECD, extracellular domain; EST, expressed sequence tag; FISH, fluorescent in
situ hybridization; kb, kilobase; RNAi, RNA interference; siRNA, short interfering
RNA; SmGCP, Schistosoma mansoni gynaecophoral canal protein; SmTbRI,
Schistosoma mansoni transforming growth factor-beta type I receptor; SmTbRII,
Schistosoma mansoni transforming growth factor-beta type II receptor; TGF-b,
transforming growth factor-beta; TM, transmembrane
* To whom correspondence should be addressed. E-mail: ploverde@sfbr.org
PLoS Pathogens | www.plospathogens.org June 2006 | Volume 2 | Issue 6 | e54 0536debilitating disease that afﬂicts 200 million people [31].
Growth, migration, and development of the parasitic worms
in their host are believed to be controlled, in part, by signals
received from the host. Schistosoma mansoni worms in their
niche in the deﬁnitive host are bathed in host molecules
(hormones, antibodies, cytokines, growth factors, etc.) Data to
date indicate that schistosomes are in a dynamic process of
receiving and responding to host molecules. Receptors
present on the parasite surface process the repertoire of
signals in such a way that promotes development, and guides
the worms through their journey from site of infection to
their ﬁnal destination [32,33]. Furthermore, the absolute
prerequisite for the female worm to reside within the
gynaecophoric canal of the male worm, in order to develop
and maintain its reproductive activity, highlights the signiﬁ-
cance of a set of self signals on the growth and development
of the parasite and differentiation of its tissues [34].
The diverse effects produced by members of the TGF-b
superfamily on a wide array of cell types stimulated the
investigation of this signaling pathway as a plausible means of
signal transmission that could be involved in the parasite
growth and maturation. Earlier studies identiﬁed members of
the TGF-b pathways in S. mansoni. A TGF-b type I receptor
(SmRK1 or SmTbRI) was found to be localized to the parasite
surface [35] and to mediate phosphorylation and subsequent
activation of receptor-regulated schistosome Smad2
(SmSmad2) [36,37], but not SmSmad1 [36,38]. The molecular
characterization of SmTbRI and the elucidation of its role in
transmitting the signal in parasite tissues have encouraged
the search for the type II receptor. One recent study reported
the isolation of three transcripts encoding a TGF-b type II
receptor: one, a full length receptor with 59- and 39-UTRs
designated SmRK2; a longer form lacking the stop codon and
a3 9-UTR (SmRK2a); and a third truncated variant (SmRK2b)
that encodes the ﬁrst 53 amino acid (aa) residues of the N-
terminal extracellular domain (ECD), followed by an inserted
ten-residue hydrophobic domain [39].
In addition to the upstream components such as the type II
receptor, the search for TGF-b–responsive gene(s) is impor-
tant since the modulation of target gene expression dictates
the phenotypic outcome of growth factor activation based on
the cellular context. To that end, searching protein databases
for genes possibly regulated by TGF-b resulted in the
identiﬁcation of a protein homolog to a secreted matrix
protein whose expression is greatly induced by TGF-b in
human lung adenocarcinoma cell line (big-h3) [40]. The
schistosome counterpart is an 86-kDa glycoprotein that is
expressed on the surface of adult female worms. In male
worms, its surface expression is limited to the gynaecophoric
canal (S. mansoni gynaecophoral canal protein [SmGCP]), the
siteof direct interaction between the mating pair [41]. SmGCP
contains multiple short, conserved repeats that exhibit
homology to the developmentally regulated neural cell
adhesion molecule fasciclin-I from Drosophila melanogaster [42].
In this study, we report the isolation and characterization
of the full-length coding sequence of S. mansoni TGF-b type II
receptor (SmTbRII) that extends the cDNA sequence an extra
1.5 kilobases (kb) longer than was previously reported
(SmRK2a). The extra cDNA sequence encodes the correct C-
terminal end of SmRK2a, a3 9-UTR, as well as the poly-
adenylation signal and poly A tail. We also demonstrate a role
for host ligands in regulating schistosome gene expression by
showing the direct involvement of SmTbRII in human TGF-b
ligand binding. In addition, we report the identiﬁcation of
SmGCP [42] as a TGF-b target gene in the parasitic helminth S.
mansoni, and we present evidence for its transcription
activation by human TGF-b1 via an SmTbRII-dependent
mechanism in the parasite itself.
Results
SmTbRII: Identification, Cloning, and Sequence Analyses
of the cDNA and Description of Genomic Organization
Two overlapping expressed sequence tag (EST) clones
(CD126244 and CD069595) showed similarity to part of the
kinase domain of the TGF-b type II receptor from different
organisms and were found to span a region in the intra-
cellular kinase domain of the isolated receptor corresponding
to base pairs (bp) 755–1,608 of the submitted cDNA sequence.
The use of a PCR product derived from these EST clones as a
screening probe for S. mansoni cDNA expression libraries
resulted in the isolation of ﬁve positive clones. The isolated
cDNA clones were sequenced from both strands, and the
sequence data were analyzed using the National Center for
Biotechnology Information ‘‘BLASTX’’ homology search of
protein databases. It was found that these clones belong to
TGF-b receptor family of type II subclass. Of these, a 3,932-bp
cDNA clone was found to encode a protein of 815 aa, which
contains the entire predicted coding sequence of TGF-b type
II receptor. Sequence comparisons demonstrated that the
schistosome receptor shows highest similarity to mammalian
Activin type II receptors (rat, mouse, and human, respec-
tively). These results were based on comparison of the kinase
domains of the isolated clone and other members of type II
receptor subfamily. However, the N-terminal ECD and the
TM domains showed greatest similarity to Activin type II
receptors from the spotted green puffer, Tetraodon nigroviridis,
and the zebra ﬁsh, Danio rerio, and to BMP type II receptor of
the giant paciﬁc oyster, Crassostrea gigas. Further analysis using
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S. mansoni Type II TGF-b Receptor
Synopsis
Schistosomes are multicellular parasites that infect 200 million
people worldwide. Schistosome development in the human host
likely involves host molecules that regulate biological processes of
the parasite. Members of transforming growth factor-beta (TGF-b)
superfamily play pivotal roles in development in multicellular
organisms. TGF-b signaling requires ligand binding to a specific
surface receptor, TGF-b type II receptor. The authors isolated the
schistosome TGF-b type II receptor (SmTbRII), which was found to
be biologically active and responded to stimulation by host TGF-b.
The gynaecophoric canal is a ventral groove in the male worm in
which the female must reside for sexual maturity. Gynaecophoral
canal protein (GCP) is a protein whose expression in male worms is
limited to the gynaecophoric canal and is implicated in female
reproductive maturation. GCP expression was found to be regulated
by human TGF-b. Knocking down the expression of SmTbRII resulted
in a concomitant reduction in the expression of GCP, providing
evidence for the direct involvement of SmTbRII-mediated, host TGF-
b–induced regulation of schistosome gene expression. This study
implicates the TGF-b signaling pathway in worm pairing, a
prerequisite for female egg production. Because the eggs produced
by the worm pairs are responsible for pathogenesis, the authors’
research identifies potential targets for intervention.Dense Alignment Surface method (DAS; http://www.sbc.su.se/
;miklos/DAS) [43] predicted a single TM domain spanning aa
residues 139 to 164. The protein sequence apparently lacks
membrane-anchoring motifs such as GPI (glycosylphosphati-
dylinositol)-anchoring signals or signal peptides.
The cDNA clone reported in this study, SmTbRII, contains
a 64-bp 59-UTR and a 1.4 kb 39-UTR, with a poly A tail and a
putative ‘‘ATTAAA’’ polyadenylation signal located 21 bp
upstream of the poly A tail. The use of the full-length
SmTbRII cDNA sequence to screen S. mansoni genomic
databases resulted in the assembly of several contigs to
construct the genomic gene of TGF-b type II receptor (Figure
1). The 26 kbp gene consists of nine exons and contains about
2.9 and 2.4 kbp of genomic DNA located upstream and
downstream of the ﬁrst and last exon of SmTbRII, respec-
tively. Analysis of the genomic sequence of SmTbRII and
comparison to previously identiﬁed cDNA clones revealed
the presence of two transcripts predicted to produce two
different isoforms of type II receptor. One transcript encodes
the sequence of the previously reported receptor (550 aa;
SmRK2) [39]. A second, longer mRNA translates into the
receptor described in this report (SmTbRII). These tran-
scripts are produced from the same gene by alternative
splicing of the last two exons (exons 8 and 9) (Figure 1).
SmRK2 and SmRK2a were reported to contain 100- and 105-
bp 59-UTRs, respectively [39]. Both cDNAs contain an extra
42 bp upstream of what was found in SmTbRII, which is also
present in the genomic DNA and likely represents part of the
ﬁrst exon. The rest of the 59-UTR of SmRK2, SmRK2a, and
SmTbRII is almost identical (below).
The 59-end of SmRK2a shows a 1-bp deletion at position
110, as compared to that of SmRK2 and SmTbRII, which
results in a frame shift that deletes amino acids 2 and 3,
glutamate and cysteine. The sequence of the corresponding
genomic DNA was found to match that of SmRK2 and
SmTbRII, but not SmRK2a. Therefore, we believe that the
deletion could be attributed to a sequencing error of the
SmRK2a cDNA. Regarding the 39-ends, SmRK2a encodes a
754–aa protein that was proposed to lack the stop codon [39].
The authors explained that this transcript could represent a
nonfunctional, rapidly degraded mRNA, or might encode a
functional protein albeit lacking the stop codon [39]. DNA
sequence data retrieved from genomic DNA databases
revealed that the C-termini of SmTbRII and SmRK2a and
the 39-UTR of SmTbRII are encoded by exon 9 of the gene.
Thus, these data indicate that the cDNA sequence of SmRK2a
is incomplete and that SmTbRII sequence presents the
missing 39-end of SmRK2a.
The genomic sequence of the exon representing the region
spanning the stop codon and the 39-UTR reported in SmRK2
[39], shows that what was thought to be a poly A tail in SmRK2
is in fact a stretch of eight adenosine (A) nucleotides followed
by two guanosines (G) then another three As (Figure S1A,
pound [#] sign) and is not the actual poly A tail of SmRK2
Figure 1. Genomic Structure of S. mansoni TGF-b Type II Receptor Gene
A schematic representation of the genomic locus of S. mansoni TGF-b receptor II (middle) and the two alternatively spliced transcripts, SmTbRII (top)
and SmRK2 (bottom). The sizes of introns are represented in kb and that of exons (represented as cylinders) are in bp. The red exon is unique for SmRK2
and the blue exon is unique for SmTbRII. Block arrows represent the two receptor isoforms, SmRK2 (red) and SmTbRII (blue) with locations of start and
stop codons indicated.
DOI: 10.1371/journal.ppat.0020054.g001
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S. mansoni Type II TGF-b Receptortranscript. Further evidence for this is that a consensus
polyadenylation signal could not be found in an appropriate
location respective to the proposed poly A tail in SmRK2
cDNA. It is likely that the approach employed to isolate the
full-length cDNA, 39 RACE (rapid ampliﬁcation of cDNA
ends) using poly dT primer, generated this error. Careful
screening of the genomic sequence in search of putative
polyadenylation signals for this transcript revealed the
presence of a potential signal 309 bp downstream of the
reported SmRK2 poly A stretch (Figure S1A, asterisk [*]). In
order to determine if this consensus sequence serves as an
actual polyadenylation signal, we designed PCR primers
upstream and downstream of it (Figure S1A; Table S1). When
using cDNA templates, the expected PCR products could be
ampliﬁed only when a forward primer (F1) was used in
combination with either one of two reverse primers located
upstream of the putative polyadenylation signal (R1 and R2;
Figure S1B, panel I), but not with reverse primers located
about 110 bp (R3) and 730 bp (R4) downstream of the
proposed signal (Figure S1B, panels I and II). Similarly, no
products were obtained when another forward primer (F2; a
complementary sequence of R2) was used with reverse
primers R3 and R4 (Figure S1B, panel III).
In addition, other PCR reactions were designed to address
the relationship of the two transcripts. Primers F1, which is
common for both SmRK2 and SmTbRII (exon 7), and F2,
which is unique for SmRK2 and located close to the 39-end of
exon 8, were used with a reverse primer (R5), which is unique
for SmTbRII (exon 9). Only F13R5 (Figure S1B, panel II), but
not F23R5, reaction (Figure S1B, panel III), gave the expected
PCR product with cDNA templates. These results indicate
that the two transcripts are independently represented in the
cDNA. Genomic DNA templates, either extracted genomic
DNA or isolated bacterial artiﬁcial chromosome (BAC)
clones, gave the expected products in all the reactions (Figure
S1B). All PCR products were sequenced, and sequence
information matched that obtained from the database.
The third truncated transcript reported in the Forrester et
al. study [39] was described as encoding a 63 aa–long peptide
and was suggested to function as a membrane anchor, act as a
soluble ligand trap analogous to Follistatin, Noggin, or
Decorin, or act as a membrane-bound accessory protein to
promote ligand binding. This transcript, indeed, represents
the ﬁrst exon that covers the 59-UTR and the following
sequence that encodes the ﬁrst 53 aa followed by a 33 bp–long
intron that translates into 10 aa followed by a stop codon
(Figure 1). The ampliﬁcation of this DNA fragment could
simply be attributed to contamination of cDNA preparations
with genomic DNA that was carried over from total RNA
extraction steps. This is consistent with the authors’ notion
that this sequence may originate from an unspliced intron,
since it starts and ends with the classical GT-AG intron
boundary sequences [39].
Detection of Native SmTbRII Protein in Schistosomes
SmTbRII was detected in schistosome extracts using
afﬁnity-puriﬁed IgG directed against the N-terminal 153 aa
of SmTbRII, SmTbRII-N (41–193). In principle, the antibody
used in these assays can detect both forms of type II receptor.
As expected, two major protein bands were observed in
Western blots using speciﬁc anti-type II receptor antiserum.
The faster migrating component is about 62 kDa (Figure 2,
panel C, arrow 1), whereas the higher molecular weight
protein is about 92 kDa (Figure 2, panel C, arrow 2). These
data provide further evidence for the presence of two related
proteins. The shorter is 550 aa long (SmRK2; 62.2 kDa
deduced size) described by Forrester et al., [39], and the larger
is 815 aa (SmTbRII; 92.6 kDa deduced size). The detection of
the two forms of the receptor in NP-40 extracts indicates that
these receptors are associated with the tegument (outer
covering) of the parasites. NP-40 extracts probed with pre-
immune rabbit IgG, as a negative control, did not show any
signiﬁcant reactivity (Figure 2, panel B).
In immunoﬂuorescence assays, SmTbRII and/or SmRK2
could be detected in adult worm pairs in either cryosections
(unpublished data) or in live or acetone-ﬁxed whole parasites
(Figure 3). Anti-receptor II antibody reactivity with native
antigen(s) in live parasites was conﬁned to the parasite
surface in female worms (panels F and I) and in male worms,
to the tubercles (panel B), as well as in the gynaecophoric
canal (panel C). Antibody reactivity patterns in acetone-ﬁxed
parasites showed that receptor II is also localized at the
interface between the parasite and its host, the oral and
ventral suckers (panel K), and the lining tegument of the
esophagus (panel L). No speciﬁc (far-red) ﬂuorescence could
be visualized when pre-immune rabbit IgG was used (Figure
S2, panel C).
Detection of SmTbRII Transcripts
A RT-PCR semi-quantitative analysis was employed to
assess the level of receptor II mRNA throughout schistosome
development. Compared to the constitutively expressed
control, a-tubulin, SmTbRII exhibited relatively steady
expression levels throughout development. On the other
hand, SmTbRI showed lower expression levels in develop-
mental stages at earlier than 15-d postinfection, while the
overall expression pattern of SmTbRI was signiﬁcantly lower
than that displayed by SmTbRII (Figure 4).
TGF-b type II receptor transcripts were also detected in
adult worm pair parafﬁn sections. By using an anti-sense
cRNA probe designed to the N-terminal region of SmTbRII,
we detected the transcripts in the vitelline cells and gut
epithelial cells (Figure 5, panel IIC), as well as subtegumental
Figure 2. Identification of Native TGF-b Receptor II in NP-40 Extract of S.
mansoni Adult Worm Pairs
Coomassie blue–stained SDS gel (panel A), and Western blot analysis of
NP-40 schistosome extract using an IgG fraction of pre-immune (panel B)
and SmTbRII-immunized (panel C) rabbit sera. Arrows 1 and 2 point to 62
and 92 kDa isoforms, respectively.
DOI: 10.1371/journal.ppat.0020054.g002
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S. mansoni Type II TGF-b Receptorcells (Figure 5, panel IIIC). As expected, P14, an eggshell
precursor transcript employed as a positive control, was
localized to the vitelline cells in adult female worm sections
with no reactivity in male sections (Figure 5, panel IC). No
speciﬁc reactivity could be observed in the negative control
sections probed with sense cRNA probe of SmTbRII-N
(unpublished data).
In Vitro Interaction of SmTbRII with SmTbRI
Schistosome TGF-b receptor interactions in vitro were
evaluated by co-immunoprecipitation. The degree of recep-
tor interactions were expressed as the percentage values of
the precipitated radiolabeled product compared to the input
material. Incubation of the N-terminal domains of the two
receptors resulted in a 2-fold enhancement (Figure 6, panel
A, lane 3) over background precipitation of
35S-SmTbRI-N
with S-protein agarose beads (Figure 6, panel A, lane 2). Non-
speciﬁc background precipitation was removed in later
experiments (Figure 6, panel B) by pre-absorbing
35S-labeled
SmTbRI-N with S-protein agarose beads. Compared to the
interactions in the absence of ligand, adding 1 nM of
recombinant human TGF-b1 (Figure 6, panel A, lane 4 and
panel B, lane 5) or, to a lesser extent, 5 nM recombinant
human Bone Morphogenetic Protein-2 (BMP2; Figure 6,
Figure 3. Whole-Mount S. mansoni Adult Worm Immunofluorescence
S. mansoni adult worms were probed with anti-SmTbRII rabbit IgG and pre-immune rabbit IgG (Figure S2), followed by biotin-conjugated anti-rabbit
IgG. Reactive complexes were detected using streptavidin Alexa Fluor 647 conjugate and analyzed with a Bio-Rad MRC1024 confocal laser microscope.
Anti-SmTbRII reactivity is shown in a live male worm (?) (panels A–C) in different laser sections in tubercles (T) (panel B) and gynaecophoric canal (G)
(panel C). Specific surface fluorescence is also shown in live female worms (/) (panels F and I), whereas green fluorescence fields show the non-specific
auto-fluorescence in vitellaria (V), oviduct (OvD) (panel E), and ova (Ov) (panels E and H). An acetone-fixed male worm (?) shows anti-SmTbRII reactivity
in the gynaecophoric canal, oral (Os) and ventral suckers (Vs) (panel K), and in esophagus (O) (panel L). Panels A, D, G, and J are phase-contrast fields of
the fluorescent fields B and C, E and F, H and I, and K and L, respectively.
DOI: 10.1371/journal.ppat.0020054.g003
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S. mansoni Type II TGF-b Receptorpanel A, lane 5, and panel B, lane 7) signiﬁcantly enhanced
the interaction of type I and type II receptor N-termini.
Furthermore, the receptor interaction showed a dose-
dependent enhancement in response to TGF-b1 (Figure 6,
panel B, lanes 2–5). Neither Activin A (2.0 nM) nor BMP4 (5.0
nM) stimulated N-terminal domain interactions (Figure 6,
panel B, lanes 6 and 8, respectively). Thus, these results
demonstrate that the interaction of the N-terminal regions of
the two receptors is dependent on the presence of TGF-b
ligand. Further interaction assays showed that the kinase
domains of both receptors readily associate, while no
signiﬁcant interaction was observed between the receptors’
C-termini (unpublished data).
These data demonstrate that human TGF-b1, and to a
lesser extent human BMP2, could stimulate the interaction of
the N-terminal domains of SmTbRII and SmTbRI, which
suggests that the parasites may utilize the human growth
factors in their developmental processes. The extent to which
the signal could be transduced in the parasite tissues, which is
whether or not TGF-b–induced receptor interaction is
functional, was next investigated. In order to address this
point, an SmSmad2/SmSmad4 interaction assay, similar to
that previously described [38], was designed. In the previous
report, the constitutively active, ligand-independent mutant
form of type I receptor (SmTbRI-Q/D), but not wild-type
SmTbRI (SmTbRI-wt) could stimulate the SmSmad2/
SmSmad4 interaction. In this study, we adopted the same
approach and examined the SmSmad2-MH2 interaction with
SmSmad4 in the presence of wild-type receptors, SmTbRII
and SmTbRI, in the absence or presence of either 1 nM
human TGF-b1 or 5 nM human BMP2. Constitutively active
and wild-type SmTbRI were used as positive and negative
controls, respectively. In case of reactions containing both
wild-type receptors in the absence of ligand (Figure 7, panel
A, lane 5) or in the presence of BMP2 (Figure 7, panel A, lane
7), an SmSmad2/SmSmad4 interaction was obtained that is
below that of the background reaction (in absence of
receptors; Figure 7A, lane 2) or of the negative control
reaction (in the presence of wild-type receptor I alone; Figure
7A, lane 4). In contrast, in the presence of TGF-b1, a
signiﬁcant increase in interaction of SmSmad2-MH2 domain
with SmSmad4 was observed (Figure 7, panel A, lane 6), and
was comparable to what was obtained in the positive control
reaction with SmTbRI-Q/D (Figure 7, panel A, lane 3). On the
other hand, when a mutant, non-phosphorylatable form of
SmSmad2-MH2 domain (SmSmad2-MH2/AAA) was used, no
signiﬁcant enhancement in the interaction with SmSmad4
could be detected in any of the reactions containing type I
receptor alone or along with type II receptor (Figure 7, panel
B). Therefore, these data demonstrate that the TGF-b
stimulated a functional interaction of type II and type I
receptors, which in turn relayed the signal down to SmSmad2
and promoted its interaction with SmSmad4.
Identification of SmGCP as a S. mansoni TGF-b Target
Gene
SmGCP was found to exhibit homology to three related
proteins: D. melanogaster fasciclin I [44]; mouse and OSF2
(human osteoblast speciﬁc factor 2) [45], a homophilic
adhesion molecule that plays a role in bone formation; and
lastly the big-h3 [40]. Each contains repeated, short, highly
conserved regions within more divergent homologous do-
mains (fas1 domain) of approximately 140–150 aa [40,44].
SmGCP contains two of the fas1 domains between residues
43–306 and is localized to the adult parasite surface (restricted
to the gynaecophoric canal in male worms), although it lacks a
consensus TM domain or a GPI-anchoring signal [42]. The ﬁrst
step in evaluating the SmGCP gene as a possible target for
TGF-b regulation was to determine its expression pattern
throughout development. Semi-quantitative RT-PCR was
performed in which SmGCP-speciﬁc primers were used to
amplify a PCR product of approximately 300 bp. Figure 8A
shows that SmGCP exhibits an expression peak at 28 d
postinfection (lane 7), which coincides with worm mating. A
similar expression level was observed in adult male worms
(lane 11), although relatively low levels are observed in 15-d-
old or earlier schistosomules and parasite eggs (lanes 3–5).
Figure 4. Semi-Quantitative RT-PCR Analysis of SmTbRII
Top panel shows agarose gel separation of the PCR products of SmTbRII
(middle), SmTbRI (bottom) and the constitutively transcribed control, a-
tubulin (top). Lanes are numbered and the respective stages are listed at
the bottom of the bar graph. The bar graph representation shows the
percentage values of the optical densities in pixels of the PCR bands of
SmTbRII (gray bars) and SmTbRI (white bars) compared to the
corresponding band of a-tubulin control from the same stage. Values
were calculated from three independent PCR amplifications (Error bars
represent standard deviation values). Samples included in the assay were
the hepato-pancreas regions of the intermediate host; uninfected and
30-d–infected B. glabrata snails, which represent different stages of
daughter sporocysts; parasite eggs obtained from the liver of Syrian
golden hamsters infected with 5,000 cercariae; cercariae shed and
collected from infected snails; and stages representing different time
points during schistosome development in mammalian host, obtained
by perfusion of infected hamsters for the specified time (15–45-d-old
worms). Adult male and female worms, separated after perfusion, were
also included in the assay. Samples were subjected to total RNA
extraction and cDNA synthesis, followed by PCR amplification using
specific primer pairs.
DOI: 10.1371/journal.ppat.0020054.g004
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S. mansoni Type II TGF-b ReceptorThe responsiveness of SmGCP to induction by members of
the TGF-b family was also examined. Total RNA was
extracted from adult worms that were incubated in culture
media supplemented with either 1 nM of TGF-b1 or 5 nM of
BMP2, and subjected to semi-quantitative RT-PCR. Tran-
script levels for SmGCP and identiﬁed members of TGF-b
signaling pathways were examined using this approach.
Compared to untreated worm controls (Figure 8B, lane 1),
an approximately 2-fold increase of SmGCP expression was
observed in adult worms treated with human TGF-b1 (Figure
8B, lane 2), although BMP2 treatment resulted in a slight
decrease in SmGCP levels (Figure 8B, lane 3). No signiﬁcant
differences were detected in levels of SmTbRI, SmSmad1,
SmSmad2, or SmSmad4 compared to untreated controls
(unpublished data).
The above data indicate that SmGCP expression is
modulated by human TGF-b. To determine whether this is
dependent on stimulation of the TGF-b signaling pathway or
a secondary event incited through stimulation of a different
signaling network as part of a more generalized cellular
response, we investigated the effect of blocking TGF-b
signaling on the expression of SmGCP, by employing RNA
interference (RNAi) to knock down type II receptor as the
initial event of TGF-b signaling.
Freshly perfused 26-d-old and 33-d-old worm pairs trans-
formed with TGF-b type II receptor–speciﬁc short interfering
RNA (siRNA) were left untreated or treated for 24 h with 1
nM human TGF-b1. RT-PCR data demonstrated that
SmTbRII-speciﬁc siRNA treatment did diminish the levels
of SmTbRII mRNA about 3- to 4-fold (25%–30% of the levels
of untreated samples; Figure 9, panel B, lanes 3, 4, 7, and 8).
Moreover, not only did SmTbRII-siRNA treatment result in a
concomitant reduction in SmGCP levels (there was 2- to 3-
fold reduction in levels of SmGCP compared to untreated
samples; Figure 9, panel D, lanes 3 and 7), but SmGCP also
failed to respond to human TGF-b1 induction (Figure 9,
panel D, lanes 4 and 8) as opposed to what was observed in
non-transformed parasites (Figure 8B, lane 2, and Figure 9,
panel D, lanes 2 and 6). None of the other cDNA species that
were used as controls for PCR ampliﬁcation (SmTbRI,
Figure 5. Localization of SmTbRII mRNA Transcripts in Tissue Sections of S. mansoni Adult Worms by FISH
Column A represent phase-contrast fields, Column B represent non-specific autofluorescence fields observed in vitelline lobules (V) using green
fluorescence filter (522 nm) and Column C shows specific probe reactivity as represented by far-red fluorescence using 680 nm filter. Row (I) shows
sections of a male (?) and a female (/) worm probed with the positive control cRNA probe (the antisense strand of eggshell protein P14). Specific
fluorescence could be observed in the vitellaria (V) of the female worm. As expected, no specific fluorescence could be observed in male worm sections.
Specific reactivity of SmTbRII antisense probe could be seen in vitelline cells (V) and gut epithelial cells (G) in a female worm section (panel IIC) and in
subtegumental cells (STC) in a male worm section (panel IIIC). No significant fluorescence could be seen in the negative control reaction using SmTbRII
sense cRNA strand (unpublished data).
DOI: 10.1371/journal.ppat.0020054.g005
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S. mansoni Type II TGF-b ReceptorSmSmad1, SmSmad2, and SmSmad4) showed any signiﬁcant
variation that could be attributed to different treatment
regimens (Figure 9, panels C, E, F, and G), indicating that the
responses were speciﬁc and triggered by SmTbRII-siRNA
treatment. These gene products, although part of the same
pathway as SmTbRII, are not directly regulated by TGF-b,a s
mentioned above.
Discussion
In this study, we report the identiﬁcation of type II TGF-b
receptor in S. mansoni, which represents a crucial step in
elucidation of the source and subtype of the ligand(s) that
regulate the biological events stimulated by these pathways
and subsequently determine the ultimate outcome in terms of
phenotype. Genomic DNA sequence information gathered
from S. mansoni databases and validated by sequencing
SmTbRII-positive genomic clones isolated from the BAC
library revealed the genomic organization of the SmTbRII
cDNA cloning and gene. RT-PCR data demonstrated the
presence of two independent transcripts that give rise to two
different TGF-b type II receptor isoforms. These transcripts
are products of the same gene generated by alternative
splicing of the last two exons. The amino acid sequence and
BLAST search data show that SmRK2 [39] encodes a receptor
that lacks the last 40 aa of the putative kinase domain.
Consequently, the S. mansoni TGF-b type II receptor under-
goes alternative splicing to produce transcripts that give rise
to different length receptors that might exhibit different
kinase activities. These different type II receptors may signal
in different cells or developmental stages cooperating with
SmTbRI or another unidentiﬁed type I receptor. Previous
studies on Xenopus laevis activin receptor II, ActRII [46], and
mouse ActRII gene [47], as well as human TGF-b type I
receptor SKR2 [48], reported multiple mRNA variants that
give rise to C-terminally truncated isoforms for each
receptor. This led Xu and his coworkers [48] to propose that
the addition of the poly A tail to alternative exons at the
carboxyl-terminal coding exon–intron junction could repre-
sent a common feature of both TGF-b type I and type II
receptor genes. Therefore, alternative splicing generates
transcripts encoding products that vary in length and
subsequently in their kinase activities and target phosphor-
ylation sites, a feature that may add to the heterogeneity of
biological effects of individual ligands.
The semi-quantitative RT-PCR results show that the type II
receptor exhibits a relatively constant transcription level
throughout the parasite lifecycle that is 3- to 5-fold higher
than that displayed by SmTbRI. This suggests the presence of
a second type I receptor that may cooperate with SmTbRII in
the stages in which SmTbRI shows a signiﬁcantly lower
expression level, such as the early stages of development [35],
and stages involving the intermediate host. Furthermore,
SmTbRI was found not to mediate the signals transmitted
Figure 6. In Vitro Interaction of Amino- (N-) Terminal Domains of SmTbRI and SmTbRII
Interaction of the in vitro translated non-labeled N- terminal domain of SmTbRII with
35S-labeled N-terminal domain of SmTbRI, in the presence or
absence of different TGF-b ligands (panels A and B) or varied amounts of different TGF-b1 (panel B). Ligand concentrations (in nM) are shown at the top
of each lane. Reactions were precipitated using S-protein agarose beads (EMD Biosciences, Novagen). Precipitated products were separated by SDS-
PAGE and subjected to autofluorography. In vitro translated products (5% and 20 %) of input radiolabeled products are shown in the left lane of panels
A and B, respectively. Background precipitation of
35S-labeled-SmTbRI-N by S-protein agarose beads is shown in lane 2, panel A. The background
reactivity was removed in later experiments by pre-clearing
35S-SmTbRI-N by treatment with the S-protein agarose beads (panel B) prior to use in
interaction assay. Percentage values of precipitated reactive radiolabeled product of each reaction are shown at the bottom of each lane.
DOI: 10.1371/journal.ppat.0020054.g006
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S. mansoni Type II TGF-b Receptorthrough SmSmad1 [36,38], a fact that supports the presence
of a second SmTbRI receptor capable of interacting with and
activating SmSmad1. An understanding of the performance
of the different type II receptor isoforms (SmRK2 and
SmTbRII) in different signaling contexts and their cellular
localization and expression patterns are issues that await
further investigation. The phenomenon of alternative splic-
ing, of different exons at the C-terminal end, was reported
before in S. mansoni SER, an epidermal growth factor receptor
ortholog [49].
The detection of both TGF-b type II receptor isoforms in
the NP-40 extracts of adult worm pairs, which represents a
pool of outer tegument proteins, provides evidence that both
isoforms are in fact expressed in the adult stage. They are
present in the tegument where the type II receptor, as the
initial signaling component in the TGF-b pathway, is
anchored into the surface and may respond to both host
and self signals. Such expression proﬁles and the localization
of TGF-b type II receptor at the interface between the
parasite and its host was further conﬁrmed by immunoﬂuor-
escence assays on whole-mount adult worms as well as on
adult worm sections. The detection of either or both of the
two isoforms on the surface of live parasites (tubercles and
gynaecophoric canal in male worms and general surface
localization in females) and in the lining of the esophageal
canal of ﬁxed parasites (Figure 3), highlights the fact that the
TGF-b type II receptor is actively engaged in dynamic
signaling processes at the host–parasite interface. Our results
are in agreement with localization data reported for SmRK2
that showed intense surface staining in both female and male
worm sections, which indicated that SmRK2 exhibits teg-
umental expression [39]. It can be concluded from the report
of Forrester et al. [39] that the observed expression pattern
could be representative for either or both isoforms of type II
receptor since the utilized antibody reagents used in that
study were generated against an N-terminal synthetic peptide
that is shared in both isoforms.
The ﬂuorescent in situ hybridization (FISH) assay (Figure 5)
provided an additional method for detection and localization
of type II receptor transcript. The detection of the transcripts
in the subtegumental cells is consistent with the production
of SmTbRII in the tegument and its insertion into the
parasite’s surface. In addition, the type II receptor transcripts
were also detected in gut epithelia and vitelline cells. This
may indicate that the receptor could be involved in other
signaling processes leading to sexual and digestive tissue
development and differentiation. The type II transcript and
protein distribution proﬁles are consistent with previous
studies that reported the localization of components of TGF-
b signaling pathway, SmTbRI [50], SmSmad2 [37], and
SmSmad4 [38], to digestive tract and male and female
reproductive tissues. Furthermore, the RT-PCR results
demonstrate that type II receptor shows little variation
throughout the parasite lifecycle, an observation that may
indicate its involvement in parasite growth and development
in different stages.
Interaction assays were designed to identify the domain(s)
involved in receptor complex formation. Our results dem-
onstrate that in the absence of ligand, full-length SmTbRI and
SmTbRII showed no signiﬁcant interaction. However, the
ECD of the two receptors exhibited ligand-dependent
interaction. Furthermore, the kinase domains of the recep-
tors displayed autonomous interaction, whereas the C-
termini showed no afﬁnity toward each other. These data
are in agreement with previous studies, which reported that
the interaction between the TGF-b receptors depends on the
ligand binding to either type II receptor followed by the
recruitment of receptor I, as in the case with TGF-b and
activin [19,51,52] or to both receptors as in the case of BMPs
[53–55]. Several reports have also shown the interaction of
the kinase domains of receptor I and receptor II for members
of the TGF-b superfamily [56–58].
Furthermore, our results demonstrate that the presence of
the appropriate ligand (TGF-b1 and to a lesser extent BMP2)
stimulated the association of the ECD of receptor I and
receptor II, whereas Activin A or BMP4 had no affect. These
results were surprising since the BLAST search data
categorize the S. mansoni type II receptor as belonging to
the Activin type II receptor subfamily. A similar situation was
found in Drosophila type II receptor, punt, which was initially
classiﬁed as belonging to the Activin type II receptor
subfamily, based on sequence similarities and ligand-binding
properties [59]. However, this receptor was later found to
bind to and mediate signals of the decapentaplegic (Dpp), a
Drosophila ortholog of mammalian BMP, and functionally
respond to members of the BMP family [53]. Thus, determi-
nation of the functional ligand can not be predicted based
only on sequence similarities of the kinase domain. Moreover,
Figure 7. The Transduction of TGF-b Signal to SmSmad2 via Activated
SmTbRII/SmTbRI Receptor Complex, In Vitro: Co-immunoprecipitation of
SmSmad2-MH2 and SmSmad4
35S-labeled, in vitro translated products of SmSmad2-MH2 (panel A) and
SmSmad2-MH2/AAA (panel B) were incubated with SmSmad4 in the
presence of SmTbR-I (wt) and SmTbR-II in the presence or absence of
TGF-b1 (1.0 nM) or BMP2 (5.0 nM). Radiolabeled, in vitro translated
products were co-precipitated with SmSmad4, using anti-SmSmad4-
linker IgG and Protein A Sepharose beads (Amersham Biosciences).
Background precipitation was removed by treating
35S-labeled in vitro
translated products with anti-SmSmad4-linker IgG and Protein A
Sepharose beads. The pre-cleared lysates were then used in the
above-described reactions. A positive control reaction (lane 3) was
included, in which SmSmad2-MH2, or the AAA mutant peptide, were
reacted with SmSmad4 in the presence of the active mutant form of type
I receptor, SmTbR-I (Q-D). Reactions, which contain either SmSmad2-MH2
or its AAA mutant form with SmSmad4 in the presence of wild-type
SmTbRI, represent the negative controls of the assay (lane 4).
Immunoprecipitated products were separated by SDS-PAGE and
subjected to autofluorography. Lanes are labeled to specify the input
components of each reaction. In vitro translated products (20% of input)
are shown (lane 1). Percentage values of precipitated reactive radio-
labeled product of each reaction are shown at the bottom of each lane.
DOI: 10.1371/journal.ppat.0020054.g007
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S. mansoni Type II TGF-b ReceptorBeall and Pearce [36] reported that human TbRII appears to
facilitate TGF-b binding to SmTbRI and that a chimeric
receptor composed of the extracellular domain of SmTbRI
and the intracellular domain of human TbRI could bind
human TGF-b ligand and activate a luciferase reporter system
in response to TGF-b1 and TGF-b3 but not BMP7.
In our previous work, we reported that SmSmad2
associates with SmSmad4 upon phosphorylation and activa-
tion of the former by type I receptor, SmTbRI. Only the
constitutively active mutant form of SmTbRI (SmTbRI/Q-D),
but not the wild-type receptor, could achieve this activation
in the absence of ligand or receptor II [38]. In this study we
included the type II receptor and the ligand to evaluate Smad
complex formation as a secondary event following receptor
complex formation and receptor I activation of R-Smad. Our
data show that TGF-b1 induced SmSmad complex formation
comparable to what was observed with SmTbRI/Q-D, whereas
in absence of ligand or in the presence of BMP2, SmSmad2/
SmSmad4 association was at background level (in absence of
receptors). These data demonstrate that host TGF-b1 not only
induced receptor complex formation, but also propagated
the signal to R-Smad causing its activation and association
with Smad4. This is consistent with the results of Lagna et al.
[21] who reported that agonist-induced activation of human
Smad1 (by BMP) and Smad2 (by TGF-b and activin) led to
their association with Smad4. On the other hand, the lack of
interaction between the non-phosphorylatable mutant of
SmSmad2 (SmSmad2-MH2/AAA) with SmSmad4 is in agree-
ment with a previous report that showed that in the presence
of BMP, mutation of the C-terminal phosphorylation motif of
Smad1 abolished transduction by preventing its association
with Smad4 [60].
The SmGCP exhibits surface expression in adult parasites
especially in male worms in which expression is limited to the
gynaecophoric canal and is almost absent in unisexual male
worms [42]. Interestingly, the transcription proﬁle of SmGCP
shows its peak expression in 28-d-old worms, a time that
coincides with worm pairing. This distribution pattern
emphasizes the potential role of SmGCP in male–female
interactions and the male-stimulated reproductive matura-
tion of the female schistosome [34]. TGF-b1–treated worms
displayed an enhanced expression level of SmGCP. In order
to investigate the mechanism of SmGCP expression induction
in response to TGF-b, we knocked down SmTbRII expression
to prevent initiation of the TGF-b signaling pathway. We
employed RNAi to achieve silencing of the SmTbRII gene, as
the successful use of this technique to knock down gene
transcription in S. mansoni sporocysts had been previously
Figure 8. Semi-Quantitative RT-PCR Analysis of SmGCP mRNA
The bottom panel shows the agarose gel separation of the PCR products of SmGCP (bottom), and the constitutively transcribed control, a-tubulin (top).
Panel A: Lanes are numbered and the respective stages are listed at the bottom of the panel. Panel B: Adult worm pairs (42-d-old) were left untreated
(lane 1) or treated with human TGF-b1 (1 nM; lane 2) or human BMP2 (5 nM; lane 3). Top of each panel shows a bar graph representation of the relative
PCR band intensities (%) of SmGCP compared to that of a-tubulin control. Values were calculated from three independent PCR amplifications (Error bars
represent the standard deviation).
DOI: 10.1371/journal.ppat.0020054.g008
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S. mansoni Type II TGF-b Receptordemonstrated [61,62]. In this study, we report the effective
use of siRNA as a tool to knock down a target gene expression
in late parasitic stages (28- and 35-d-old worms). The chosen
delivery method, the particle bombardment, proved effective,
as was shown in different studies reporting the use of biolistic
technique to transfect S. mansoni with different constructs
[63–68] and in our standardization experiments using an
HcRed-encoding plasmid. The observed concomitant reduc-
tion of SmGCP and SmTbRII expression in worms treated
with SmTbRII siRNA suggests that SmGCP closely follows the
expression pattern of TGF-b receptor II. In fact, the failure of
TGF-b1 to induce the expression of SmGCP in worms in
which the type II receptor was knocked down indicates a
direct relationship between the classical TGF-b pathway as
represented by type II receptor and SmGCP as a potential
target gene. However, SmGCP could represent a primary
TGF-b target gene or it could be a target gene for another
gene product that primarily induced by TGF-b pathway. A
detailed investigation involving the assessment of schistosome
Smad complex binding to the promoter region of SmGCP
will be necessary to address this point at the molecular level.
In either case, it is obvious that induction of SmGCP
expression constitutes part of the mitogenic effect exerted
by the host TGF-b ligand in schistosome.
In schistosomes, an interesting biological interplay has
evolved such that male schistosomes, via an unknown
stimulus, regulate female-speciﬁc gene expression and thus
female reproductive development and egg production [34]. In
order for the male to stimulate and to maintain female
reproductive development, there must be direct contact
between the male and the female. This is accomplished by the
female residing in the gynecophoric canal of the male. One
scenario is that the female ﬁrst stimulates the male, and the
male in turn produces signals that regulate female develop-
ment [34]. The coinciding of peak expression of SmGCP with
worm pairing, localization of SmGCP in male worms only in
the gynecophoric canal [41] and the requirement for the male
to maintain contact with the female, and induction of SmGCP
by TGFb implicates the TGFb pathway as an important
signaling component for worm pairing.
The induction of SmGCP expression by TGF-b1 provides
support for the hypothesis that schistosome gene expression
can be regulated by host ligands. It further implicates the host
ligand as a stimulator for parasite–parasite interactions via
regulating the expression of a gene that is likely involved in
such biological events. Several studies have demonstrated
involvement of host molecules in regulating biological
processes in schistosomes. Host tumor necrosis factor-a
(TNF-a), secreted as a part of the host response to eggs
trapped in liver tissues, was found to signiﬁcantly stimulate
egg laying by adult female worms [69]. In addition, human
EGF induced phosphorylation of native SER protein, the S.
mansoni homolog of EGFR. In response to human EGF
stimulation, SER was also shown to be able to activate a
Ras-responsive reporter system in epithelial canine cells and
mediate EGF responses in Xenopus oocytes [70]. The effects of
thyroid hormone, interleukin-7, and insulin on schistosome
development in the mouse host have also been demonstrated
[71].
The demonstration that schistosome type II receptor is
able to bind human TGF-b ligand provides strong evidence
for the utilization of host ligand in parasite growth and
development. However, this, in fact, does not rule out the
involvement of a self ligand or a set of ligands, as localization
studies for components of schistosome TGF-b signaling
pathways indicate that TGF-b signaling is active in sexual
tissues, a fact that implies active engagement of TGF-b
signaling in internal parasite organs as well as at the interface
with its host. This observation has been reported previously
in a study that showed type II receptors have diverse ligand-
binding abilities, and this phenomenon offers an explanation
for the wide variety of biological responses that can be
elicited by members of TGF-b family [53].
Materials and Methods
Identiﬁcation, cloning, and sequence analyses of SmTbRII. Mining
of S. mansoni DNA sequence databases resulted in the identiﬁcation of
two overlapping EST clones (CD126244 and CD069595) that show
similarity to different members of TGF-b type II receptors [72]. Based
on the EST sequences, a primer pair was designed that ampliﬁed an
Figure 9. Silencing of TGF-b–Induced Expression of SmGCP by Knocking
Down SmTbRII Expression
Semi-quantitative RT-PCR analyses for transcripts of SmGCP as well as
various components of schistosomal TGF-b signaling pathways in 35-d-
old and 28-d-old old worm pairs, untransformed and transformed with
SmTbRII-siRNA, and either left untreated or treated with TGF-b1 (1 nM).
The top panel shows the agarose gel separation of the PCR products of
SmTbRII (panel B), SmTbRI (panel C), SmGCP (panel D), SmSmad4 (panel
E), SmSmad2 (panel F), SmSmad1 (panel G), and the constitutively
transcribed control, a-tubulin (panel A). The lanes are labeled to show
detailed treatment of each sample. The bar graph representation shows
the percentage values of the optical densities in pixels of the PCR bands
for each gene compared to the corresponding band of a-tubulin control
from the same stage. Values were calculated from three independent
PCR amplifications (Error bars represent the standard deviation).
DOI: 10.1371/journal.ppat.0020054.g009
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S. mansoni Type II TGF-b Receptor859-bp PCR product from adult worm cDNA, which was cloned in
pCR2.1-TOPO vector (Invitrogen,C a r l s b a d ,C a l i f o r n i a ,U n i t e d
States) and sequenced. The DNA fragment was labeled using the
MegaPrime DNA labeling system (Amersham Biosciences, Piscataway,
New Jersey, United States) and employed to screen an S. mansoni adult
worm pair k-ZapII cDNA expression library [73]. Isolated clones were
excised in vivo and converted to pBlueScript SKþ phagmids, using
ExAssist lambda helper phage following the vendor’s instructions
(Stratagene, Mountain View, California, United States). One of those
clones was found to contain the entire coding sequence of the type II
TGF-b receptor. DNA and protein sequence analyses were performed
using programs in the Wisconsin Package Version 10.3 (Accelrys, San
Diego, California, United States).
DNA sequence analysis revealed the presence of two SphI cut sites,
one preceding the start ATG codon, while the second is about 525 bp
downstream of the start ATG codon (at bp 59 and 592 of the
submitted cDNA sequence). Two ampliﬁcation primers were de-
signed to amplify the cDNA fragment corresponding to the N-
terminal domain of the receptor (193 aa); a forward primer that
represented DNA sequence from bp 65–87 and had a BamHI cut site
inserted upstream of the start ATG codon and a reverse primer,
which represented the sequence complementary to bp 625–645 of the
submitted cDNA sequence. The PCR product was cloned into the
pCRII-TOPO vector (Invitrogen) giving rise to pSmTbRII-N(1-193)/
TOPO-II that was sequenced to conﬁrm the absence of PCR-
generated errors, digested with BamHI and SphI, and re-cloned into
the parental BlueScript-SKþ vector that was digested with the same
enzymes to generate a modiﬁed version of the cDNA clone in which
the 59-UTR upstream of the start ATG codon was removed and a
BamHI site was brought forward upstream and in frame with the start
ATG codon. The modiﬁed vector, pSmTbRII-BlueScript-SKþ, was
digested with BamHI and with XhoI, which is located at the 39-end of
the multiple cloning sites of the parent vector pBlueScript-SKþ,t o
excise the SmTbRII cDNA fragment suitable for cloning in several
vectors designed with BamHI and either XhoI or SalI at the 59- and
the 39-ends of the multiple cloning sites, respectively.
Genomic organization of SmTbRII gene. S. mansoni genomic DNA
databases from The Wellcome Trust Sanger Institute and The
Institute for Genomic Research (TIGR), were searched using the type
II receptor cDNA sequence to identify contigs that constituted the
entire gene. In addition, full-length cDNA was excised from the
parent vector, random prime-labeled, and used to screen an S.
mansoni BAC genomic library [74] to isolate BAC clones that harbor
the genomic sequence of receptor II. The isolated BAC clones were
used as templates in PCR reactions to validate the information
obtained from searching genomic DNA databases. The order of the
assembled contigs was conﬁrmed by PCR on genomic DNA extracted
from S. mansoni cercariae as well as SmTbRII-positive BAC clones
isolated from BAC library screening, using primers located on the 39-
and 59-ends of each contig and the following one. In addition, the
intron positions were conﬁrmed by PCR ampliﬁcation of DNA
fragments that represent exon–intron boundaries or two adjacent
exons, when such exons were interrupted by small introns.
Production of polyclonal antibodies against SmTbRII. The
pSmTbRII-N(1-193)/TOPO-II was used to amplify a cDNA fragment
encoding 153 aa from the N-terminal domain of the receptor and
cloned into the prokaryotic expression vector, pMAL-c2x (New
England Biolabs, Ipswich, Massachusetts, United States), downstream
and in frame with the MBP (maltose-binding protein) coding
sequence, pSmTbRII-N(41-193)/pMAL. A 67-kDa MBP fusion protein
was expressed, puriﬁed following the manufacturer’s instructions,
and used to immunize a New Zealand White rabbit. A dose of 200 lg
of the fusion protein emulsiﬁed in Freund’s complete adjuvant, as a
primary dose, was administered subcutaneously followed by 200 lgi n
Freund’s incomplete adjuvant for two booster doses each at 4-wk
intervals. An activating dose given intramuscularly (200 lgi n1 3PBS)
was used 7 d before sacriﬁcing the animal. IgG fractions were afﬁnity
puriﬁed over a Protein A-Sepharose (Amersham Biosciences) and
quantiﬁed. Pre-immune rabbit serum was processed similarly to
provide reagents for negative controls. Afﬁnity-puriﬁed IgG was used
for immunoprecipitation, immunoﬂuorescence, and Western blot
analyses.
Immunological assays. Puriﬁed IgG fractions were used to detect
the native protein in parasite extracts and in cryosections following
protocols described in previous studies [37,38]. Immunoﬂuorescence
assays on whole-mount adult worms, either live or acetone ﬁxed, were
also conducted, following a protocol similar to that used for
cryosections, to examine whether the native protein was exposed
on the parasite surface. Brieﬂy, adult worm pairs, either live or ﬁxed
for 5 min in ice-cold acetone, were incubated for 2 h at room
temperature in MEM medium supplemented with 10% fetal bovine
serum (Invitrogen), used as a blocking reagent. Incubation medium
was replaced with test and control primary antibodies (IgG fractions),
5 lg/ml diluted in the above medium, and incubated overnight at 4
8C. Samples were washed with 13PBS for four times, 5 min each, and
then anti-primary, biotin-conjugated secondary antibodies (5 lg/ml;
Molecular Probes. Invitrogen, Carlsbad, California, United States)
were incubated for 1 h at room temperature followed by a washing
step as before. Alexa Fluor-647–conjugated streptavidin (5 lg/ml;
Molecular Probes, Invitrogen) was used to visualize the reactive
antigen antibodies. Autoﬂuorescence attributed to phenolic com-
pounds could be visualized at yellow-green ﬂuorescence wavelength
(520 nm), but not at far-red ﬂuorescence (680 nm). Cyrosections and
whole-mount parasites were examined using a Bio-Rad MRC-1024
confocal microscope equipped with Krypton-Argon laser and 522-nm
and 680-nm ﬁlters (Bio-Rad, Hercules, California, United States).
Micrographs representing different laser sections of the samples were
chosen to delineate the localization of speciﬁc and nonspeciﬁc
ﬂuorescence in the examined samples.
Detection of SmTbRII transcripts: RT-PCR and FISH analyses.
Two approaches were employed to detect SmTbRII mRNA. A semi-
quantitative analysis to estimate relative SmTbRII mRNA levels in
different developmental stages was carried out by RT-PCR as
previously described [38]. In addition, gene transcripts were localized
by FISH. In the semi-quantitative RT-PCR assay, PCR products,
ampliﬁed in separate reactions each using a speciﬁc primer pair,
were separated by electrophoresis in 2% agarose gels, stained with
ethidium bromide, analyzed using a gel-documentation system
(GelDoc1000; Bio-Rad), and quantiﬁed using Quantity One software
(version 4.2.3; Bio-Rad). Negative control PCR reactions using reverse
transcription reaction mix lacking reverse transcriptase were also
included. Speciﬁc primers for the S. mansoni a-tubulin gene (bp 424–
444 and the complementary sequence of bp 777–801 as forward and
reverse primers, respectively, yielding 378-bp PCR product) were
used to amplify a PCR product that served as a constitutively
transcribed control [75]. A speciﬁc primer pair for SmTbRII (forward
primer, starts at bp 845; reverse primer, ends at bp 1,080), was used
that yields a 236-bp PCR product. Primer pairs speciﬁc for SmTbRI
(forward primer starts at bp 1,608, reverse primer ends at bp 1,894),
and SmGCP (forward primer starts at bp 818, reverse primer ends at
bp 1,114), were also used to amplify the corresponding fragments of
these gene transcripts yielding products of 287 and 297 bp long,
respectively. In addition to the above genes, SmSmad1, SmSmad2, and
SmSmad4 were similarly processed as control genes. The PCR primers
and reaction conditions that were used to amplify those products
were as previously described [38]. Due to differences in the quality of
RNA preparations included in this assay, the volumes of input cDNA
templates of each stage were varied according to normalization data
using a-tubulin control. Also, due to differences in the abundance of
the assayed cDNA species and in order to ensure that the
ampliﬁcation products were analyzed in the exponential phase and
below saturation limits (PCR plateau), the number of PCR cycles used
to amplify each cDNA was also varied. For a-tubulin, 24 cycles was
used, whereas 27 cycles were used to amplify the PCR products for
SmTbRII, SmSmad4, SmSmad2, and SmGCP, and 28 and 29 PCR
cycles were used in the case of SmSmad1 and of SmTbRI,
respectively. All variables were considered and compensated for in
data analysis.
For the FISH assay, the SmTbRII RNA probes, a test probe and a
negative control probe were prepared by in vitro transcribing and
labeling of the anti-sense and sense strands of the N-terminal domain
of SmTbRII (pSmTbRII-N (1-193)/TOPO-II) using Sp6 and T7 RNA
polymerases (Ambion, Austin, Texas, United States), respectively, and
digoxigenin-11-uridine-59-triphosphate (DIG-11-UTP; Roche Applied
Science, Indianapolis, Indiana, United States), following the manu-
facturers’ suggested instructions. An RNA probe representing the
anti-sense strand of the coding sequence of a schistosome eggshell
protein, P14, was used as a positive control, which localizes the P14
transcripts only to female vitelline cells [76]. Probe hybridization and
washing was performed using parafﬁn-embedded sections that were
de-parafﬁnized, hydrated, hybridized, and washed according to the
recommended instructions of the mRNAlocator-Hyb Kit (Ambion).
DIG-labeled probe detection was achieved by using an anti-DIG
monoclonal antibody (0.25 lg /ml; Roche Applied Science), followed
by a biotin-conjugated goat anti-mouse antibody (Molecular Probes,
Invitrogen), and the antibody complexes were visualized using
streptavidin-conjugated Alexa Fluor 647 (Molecular Probes, Invitro-
gen) in concentrations similar to that used in the immunoﬂuor-
escence assays. Sections were examined by Bio-Rad MRC-1024
confocal microscope using 522-nm and 680-nm ﬁlters.
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sequences of SmTbRII and SmTbRI were divided into three regions
each, representing the main structural domains of both receptors.
These regions were PCR-ampliﬁed from full-length cDNA clones and
cloned into the BamHI and XhoI sites of the in vitro transcription/
translation, S-protein tagged and non-tagged vectors; pCITE-4a and
pCITE-2a, respectively (EMD Biosciences, Novagen, San Diego,
California, United States). The three regions were the N-terminal
regions, which represent the extracellular TM domains (SmTbRII, bp
65–645, 190 aa; and SmTbRI, bp 19–522, 170 aa), the kinase domains
of SmTbRII (bp 845–1,773; 310 aa) and SmTbRI (bp 613–1,796; 395
aa), and the C-terminal regions that follow the kinase domains,
SmTbRII (bp 1,709–2,520; 270 aa) and SmTbRI (bp 1,696–2,361; 221
aa). Structural domains were expressed in vitro using rabbit
reticulocyte lysates (STP3; EMD Biosciences, Novagen), in which the
S-tagged proteins were synthesized with unlabeled amino acid mix,
while 35S-methionine was incorporated into the non-tagged peptides.
The full-length receptors were also cloned in these vectors as
described above. In vitro interaction reactions were assembled using
5 ll of the radiolabeled protein and 10 ll of each of the non-labeled
proteins, and up to 5 nM of different human TGF-b ligands in 10 ll
(TGF-b1, up to 1.0 nM; Activin A, 2.0 nM; and BMP2 and BMP4, 5.0
nM [R&D Systems, Minneapolis, Minnesota, United States]). Reaction
volumes were brought up to 50 ll with 13 IPP buffer (150 mM NaCl,
20 mM Tris-HCl, [pH 7.5], 2% glycerol). The reactions were incubated
for 1 h at room temperature after which protein complexes were
precipitated by adding either 30 ll of 50% pre-washed S-protein
beads (EMD Biosciences, Novagen), or 3 lg of a speciﬁc antibody
reagent (IgG fraction) directed against one of the non-labeled
proteins, which was then precipitated using Protein A-Sepharose
beads (Amersham Biosciences). Reactions were rocked at room
temperature for an extra 1 h, centrifuged, and then washed 43 with
13 IPP buffer containing 0.1% NP-40. Protein-bound beads were re-
suspended in 13 SDS sample buffer, boiled, and separated by SDS-
PAGE. The 12% gels were stained, destained, treated with the
ﬂuorographic reagent (Amplify; Amersham Biosciences), dried, and
then exposed to X-ray ﬁlm.
Treatment of S. mansoni adult worms with human TGF-b1 and
BMP2. All culture media and supplements were purchased from
Invitrogen, unless otherwise stated. Freshly perfused adult worms
were collected from infected golden hamsters [77], washed, and then
incubated overnight at 37 8C, 5% CO2 in MEM medium supple-
mented with 1 mM sodium pyruvate, 13 non-essential amino acid
solution, 13 amino acid solution, 100 U/ml penicillin, 100 lg/ml
streptomycin, 1 lg/ml amphotericin B (antibiotic antimycotic
solution), and 2 mM Glutamax-I. Recombinant human TGF-b1 and
BMP2 (R&D Systems) were added individually to about 25 pairs of
adult worms to ﬁnal concentrations of 1.0 nM and 5.0 nM,
respectively, and incubation was continued for another 24 h, after
which the medium was changed and worms were incubated for an
additional 24 h. Total RNA was extracted from untreated or TGF-b–
treated worm pairs, and cDNA was synthesized and then subjected to
PCR using different speciﬁc gene primers following the optimized
PCR conditions for each gene employing the aforementioned
protocol. PCR products were separated onto 2% agarose gels, and
processed and quantiﬁed as described above.
Silencing of SmTbRII gene expression by siRNA treatment of S.
mansoni worms. Before conducting the RNAi experiments, conditions
for schistosome transformation were optimized. The red ﬂuorescent
protein vector, pHcRed1-1 (BD Biosciences, Clontech, Palo Alto,
California, United States) was used after modiﬁcation by inserting the
cytomegalovirus immediate early promoter (PCMV) upstream of the
coding sequence yielding pCMV-HcRed. Nucleic acid (plasmids and
RNA) delivery into schistosome worms was achieved by particle
bombardment using the Helios Gene Gun particle delivery system
(Bio-Rad). Twenty lg of vector (2-fold CsCl gradient puriﬁed) was
used to prepare the bullets by coating 10 mg of 1-lm diameter gold
microcarrier particles (2-lg DNA/mg gold particles) (Bio-Rad). A
DNA/gold suspension was used to coat Teﬂon tubing (Tefzel; Bio-Rad)
following the manufacturer’s suggested conditions. Sample bullets
were used to bombard 33-d-old worms, using different helium
pressures. Each sample received two shots at the same pressure at 1 lg
DNA/0.5 mg gold particles/shot. Transformed parasites were incu-
bated in MEM medium containing 10% fetal bovine serum, 0.5%
lactalbumin hydrolysate and streptomycin and gentamicin (100 lg/ml
each), and penicillin (100 U./ml), at 37 8C, 5% CO2 for 24–48 h, and
then evaluated using a Nikon FXA ﬂuorescent microscope and a red
ﬁlter (Nikon, Tokyo, Japan). For 33-d-old worms, 400 psi was
determined to be the optimal helium pressure.
SmTbRII-speciﬁc RNAi was constructed by in vitro transcribing
pSmTbRII-N (1–193)/TOPO-II from both directions using T7 and Sp6
bacteriophage RNA polymerases (MegaScript in vitro transcription
kits; Ambion) in separate reactions. The DNA template was digested
with DNaseI, and the resulting RNA strands were annealed, puriﬁed
over a sizing column (ProbeQuant G-50 Micro Columns; Amersham
Biosciences), spectrophotometrically quantiﬁed, and then an aliquot
of about 12 lg was digested with 15 units of RNaseIII (Ambion)
following the supplier’s instructions. The resulting 20–30 bp dsRNA
(double-stranded DNA) was further puriﬁed over a different type of
sizing matrix (Micro Bio-Spin 6; Bio-Rad). An aliquot of each RNA
sample, before and after digestion, was separated on a 2% agarose gel
to assess the efﬁciency of the in vitro transcription process and the
dsRNA digestion. siRNA was used to prepare the siRNA/gold bullets
following the above protocol described for plasmid DNA except that
the amount of dsRNA was 12 lg. Freshly perfused 26-d-old and 33-d-
old worm pairs were used as target stages for particle bombardment
using SmTbRII-N–siRNA bullets. The subsequent effect on SmTbRII
and SmGCP gene expression were evaluated by RT-PCR analyses.
Control parasites were bombarded using gold bullets. Worms were
bombarded using 400-psi helium pressure. Transformed parasites
were incubated for 24 h in the previously described serum-free
culture medium, and either left untreated or treated for 24 h with
TGF-b1 (1 nM). Two days after perfusion, the 28-d-old and 35-d-old
parasites were processed for total RNA extraction, cDNA synthesis,
and PCR ampliﬁcation of a-tubulin, SmTbRII, SmTbRI, SmGCP,
SmSmad1, SmSmad2, and SmSmad4. The PCR products were gel-
separated, analyzed, and compared to the constitutively transcribed
control, the a-tubulin, as described above.
Supporting Information
Figure S1. TGF-b Receptor II Gene Showing the Relative Locations of
the Primers and the Obtained PCR Products Used to Elucidate the 39-
End of SmRK2 cDNA
(A) A sketch represents part of TGF-b receptor II gene (exons 7 and 8,
and partial sequence of 9) showing the relative locations of the
primers used to elucidate the 39-end of SmRK2 cDNA. The pound
sign (#) and asterisk (*) show the relative locations of the proposed
poly A stretch in the Forrester et al. study [39] and the putative
polyadenylation signal at the 39-end of exon 8.
(B) Agarose gels showing PCR products ampliﬁed from S. mansoni
adult worm pair cDNA templates (lanes 2), which were prepared from
a total RNA that had been treated with DNaseI, genomic DNA
extracted from S. mansoni adult worm pairs (lanes 3), and a SmTbRII-
positive BAC clone (lanes 4). A minus RT control (lanes 1) was also
included to verify absence of any genomic DNA contaminations in
cDNA preparations. Forward primers used in these experiments are
indicated to the left of each set of ampliﬁcation reactions, and reverse
primers are listed above lane numbers. Molecular size marker (M) was
run, and sizes are indicated in kb to the right of each panel. Product
sizes are listed in Table S2.
Found at DOI: 10.1371/journal.ppat.0020054.sg001 (1.6 MB TIF).
Figure S2. Whole-Mount Live S. mansoni Adult Worm Immunoﬂuor-
escence (Negative Control)
Live S. mansoni adult worms were probed with pre-immune rabbit
IgG, followed by biotin-conjugated anti-rabbit IgG. Samples were
incubated with streptavidin Alexa Fluor 647 conjugate and analyzed
with Bio-Rad MRC1024 confocal laser microscope.
(A) represents the phase-contrast ﬁeld of a male worm (?) and a
female worm (/).
(B) represents autoﬂuorescence ﬁeld viewed at 522 nm.
(C) represents the far-red ﬂuorescence ﬁeld (680 nm). Please note,
due to lack of speciﬁc ﬂuorescence in panel (C) that results in the lack
of visible details at this wavelength, the micrograph was set at high
brightness to reveal the adult worms in the ﬁeld.
O, esophagus; Os, oral sucker; V, vitellaria.
Found at DOI: 10.1371/journal.ppat.0020054.sg002 (2.2 MB TIF).
Table S1. Sequences of Primers Used in Mapping the 39-End of
SmRK2 cDNA and Their Locations Respective to Either cDNA or
Genomic Gene
Found at DOI: 10.1371/journal.ppat.0020054.st001 (31 KB DOC).
Table S2. Expected Sizes of PCR Products of cDNA or Genomic DNA
Resulted from Using Different Primer Combinations to Elucidate the
Structure of the 39-End of SmRK2 cDNA
Found at DOI: 10.1371/journal.ppat.0020054.st002 (28 KB DOC).
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Sequence data reported in this manuscript are available from
GenBank (http://www.ncbi.nlm.nih.gov/Genbank) under accession
number AY654287. Other GenBank accession numbers for the genes
or genetic material discussed in this paper are as follows: a-tubulin
(M80214); SmGCP (U47862); SmRK2 (AY550912); SmRK2a (AY285784);
and [deleted repeat of SmRK2] SmTbRI (AF031557).
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